echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > The FDA will hold an advisory committee meeting to discuss Merck and Ridgeback's oral COVID-19 treatment molnupiravir

    The FDA will hold an advisory committee meeting to discuss Merck and Ridgeback's oral COVID-19 treatment molnupiravir

    • Last Update: 2021-10-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the US Food and Drug Administration Board announced its antimicrobial Drugs Advisory Committee (AMDAC) upcoming meeting to discuss the application of molnupiravir Merck and Ridgeback's Emergency Use Authorization (EUA) of, molnupiravir is for the treatment of COVID-19 Of research antiviral drugs


    Manage COVID-19

    On November 30, the advisory committee will hold a meeting to discuss the decision to support the use of molnupiravir to treat patients with mild to moderate COVID-19


    On November 30, the advisory committee will hold a meeting to discuss the decision to support the use of molnupiravir to treat patients with mild to moderate COVID-19


    FDA 's Center for Drug Evaluation and Research, MD, Patrizia Cavazzoni said: "FDA is evaluating the safety and efficacy data submitted by Merck and Ridgeback in its emergency use authorization request, molnupiravir for a new diagnostic out COVID-19 New oral treatments for people at high risk of infection


    FDA diagnoses infection

    According to the FDA's judgment, the agency can convene an advisory committee to solicit independent external experts' advice on a variety of complex scientific, technical, and policy issues


    The meeting is scheduled as soon as possible after the company submits the EUA request


    FDA intends to provide the public with background materials for the AMDAC meeting, including the meeting agenda and committee roster, no later than two working days before the meeting


     

    Original source:

    Original source:

    https:// href="https://" target="_blank" rel="noopener">https:// https://


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.